Results 281 to 290 of about 1,261,208 (309)

Progression-Free Survival

2011
openaire   +1 more source

Osimertinib improves progression-free survival in NSCLC

The Lancet Oncology, 2018
openaire   +1 more source

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

Lancet, The, 2004
Jaap Verweij, John Zalcberg, Ian Judson
exaly  

Durvalumab boosts progression-free survival in NSCLC

The Lancet Oncology, 2018
openaire   +1 more source

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Lancet, The, 2019
Elizabeth C James, Iain A Mcneish, Andrew Dean   +2 more
exaly  

Inflammatory Breast Cancer: The Disease, the Biology, the Treatment

Ca-A Cancer Journal for Clinicians, 2010
Melissa L Bondy, Thomas Buchholz, Anthony Lucci   +2 more
exaly  

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Lancet, The, 2020
María-Victoria Mateos, Michele Cavo, Joan Bladé   +2 more
exaly  

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

Nature Reviews Clinical Oncology, 2011
John M Ebos
exaly  

Renal cancer vaccine improves progression-free survival

Inpharma Weekly, 2004
openaire   +1 more source

Osimertinib improves progression-free survival in NSCLC

The Lancet Respiratory Medicine, 2017
openaire   +1 more source